Belvedere Trading’s Celularity CELU Stock Holding History

Belvedere Trading’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,131	Closed	-$1.32M	–	351
2021 Q1	$1.32M	Buy	+13,131	New	+$1.35M	0.11%	42

Other funds holding CELU

SIC

Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return

CVSC

C.V. Starr & Co New York $192M AUM 35.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFO

Biltmore Family Office Charlotte, North Carolina $716M AUM 21.09% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Belvedere Trading's CELU Position: Q2 2021 in Review

Belvedere Trading sold out of Celularity (CELU) in Q2 2021, closing a stake of 13,131 shares — an estimated $1.32M sold.

Belvedere Trading first reported a position in CELU in Q1 2021 and held it in 1 quarter. The position peaked at $1.32M in Q1 2021. 33 funds tracked by Wall St. Rank hold CELU as of Q2 2021.

Belvedere Trading reported no remaining Celularity position as of Q2 2021 after selling out during the quarter.
Belvedere Trading sold 13,131 Celularity shares in Q2 2021, an estimated $1.32M.
Belvedere Trading first reported a position in Celularity in Q1 2021 and held it in 1 quarter.
Belvedere Trading's Celularity position peaked at $1.32M in Q1 2021.
33 funds tracked by Wall St. Rank held Celularity as of Q2 2021.

Based on Belvedere Trading's 13F filing for Q2 2021, filed 23 Jul 2021.